0000000000675855

AUTHOR

A. Ferro

showing 4 related works from this author

Vaccinazioni: stato dell’arte, falsi miti e prospettive. Il ruolo chiave della prevenzione.

2017

La pratica vaccinale in Italia è organizzativamente incardinata all’interno del Servizio Sanitario Nazionale (SSN) e nei Servizi Sanitari Regionali (SSR). I luoghi “classici” in cui viene effettuata la procedura/prestazione vaccinale sono i servizi di vaccinazione della Aziende Sanitarie Locali (ASL) o Provinciali (ASP) delle varie Regioni.

VaccinazioneprevenzioneVaccinazione; vaccini; prevenzionevacciniSettore MED/42 - Igiene Generale E Applicata
researchProduct

Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer

2017

0301 basic medicineOncologymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentHematologymedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicinePharmaceutical AdjuvantsBreast cancerOncologyTrastuzumab030220 oncology & carcinogenesisInternal medicinemedicinebusinessAdjuvantmedicine.drugEarly breast cancerAnnals of Oncology
researchProduct

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study

2018

Background: Chemotherapy plus 1-year trastuzumab is the standard adjuvant treatment of HER2-positive breast cancer. The efficacy of less extended trastuzumab exposure is under investigation. The short-HER study was aimed to assess the non-inferiority of 9 weeks versus 1 year of adjuvant trastuzumab combined with chemotherapy. Patients and methods: HER2-positive breast cancer patients with node-positive or, if node negative, with at least one risk factor (pT>2 cm, G3, lympho-vascular invasion, Ki-67 > 20%, age 35 years, or hormone receptor negativity) were randomly assigned to receive sequential anthracycline-taxane combinations plus 1-year trastuzumab (arm A, long) or plus 9 weeks tra…

OncologyTime FactorsAdjuvant Breast cancer Cardiac safety De-escalated treatment TrastuzumabSettore MED/06 - Oncologia MedicaReceptor ErbB-2medicine.medical_treatmentAnthracycline030204 cardiovascular system & hematologyBreast cancerAntineoplastic Agents ImmunologicalErbB-20302 clinical medicineTrastuzumabAntineoplastic Combined Chemotherapy ProtocolsClinical endpointAnthracyclinesskin and connective tissue diseasesAdjuvantMastectomyAdjuvant; Breast cancer; Cardiac safety; De-escalated treatment; Trastuzumab;Hazard ratioHematologyMiddle AgedChemotherapy regimenBridged-Ring CompoundImmunologicalLocalOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleTaxoidsTrastuzumab adjuvant breast cancer cardiac safety de-escalated treatmentBreast NeoplasmMastectomyHumanReceptormedicine.drugAdultBridged-Ring Compoundsmedicine.medical_specialtyTime FactorSocio-culturaleBreast NeoplasmsAntineoplastic AgentsDe-escalated treatmentDisease-Free SurvivalDrug Administration Schedule03 medical and health sciencesBreast cancerTaxoidInternal medicinemedicineHumansChemotherapyRisk factorAgedNeoplasm StagingChemotherapyAntineoplastic Combined Chemotherapy ProtocolCardiac safetybusiness.industryTrastuzumabAdjuvant; Breast cancer; Cardiac safety; De-escalated treatment; Trastuzumab; Hematology; Oncologymedicine.diseaseCardiotoxicityNeoplasm RecurrenceNeoplasm Recurrence LocalbusinessAnnals of Oncology
researchProduct

The 2014 lifetime immunization schedule approved by the Italian scientific societies. Italian Society of Hygiene, Preventive Medicine, and Public Hea…

2014

AdultSecondaryAdolescentAdolescent; Adult; Age Factors; Aged; Child; Child Preschool; Humans; Immunization Secondary; Infant; Infant Newborn; Italy; Middle Aged; Societies Medical; Vaccination; Vaccines; Young Adult; Immunization ScheduleImmunization SecondaryYoung AdultMedicalHumansAge FactorPreschoolChildImmunization ScheduleSocieties MedicalAgedVaccinesVaccinationAge FactorsInfant NewbornInfantMiddle AgedNewbornSettore MED/38ItalyChild PreschoolImmunizationSocietiesVaccineHuman
researchProduct